Torrent Pharmaceuticals reported a mixed performance in its Q4 FY26 results, with net profit declining sharply on a year-on-year basis despite strong growth in revenue and EBITDA. The pharmaceutical major posted a rise in operational performance, but higher one-time losses impacted the bottom line during the quarter.
Torrent Pharma reported a consolidated net profit of Rs 389 crore in Q4 FY26, down 21.9% compared to Rs 498 crore reported in the corresponding quarter last year. The company said it incurred a one-time loss of Rs 66 crore during the quarter, significantly higher than the Rs 24 crore one-time loss recorded in the year-ago period.
Revenue from operations jumped 41.8% YoY to Rs 4,197 crore against Rs 2,959 crore reported in Q4 FY25, reflecting strong business momentum across key segments. The company also delivered healthy operating growth during the quarter.
EBITDA for the quarter rose 40.7% to Rs 1,356 crore compared to Rs 964 crore in the same quarter last year. However, EBITDA margin slipped marginally to 32.3% from 32.6% on a YoY basis, indicating slight pressure on profitability margins despite robust revenue expansion.